Apimeds Pharmaceuticals US (APUS) Times Interest Earned (2024 - 2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Times Interest Earned came in at 1.95 in Q2 2026, up 98.31% on a YoY basis from 0.98 in Q2 2025, and up 94.03% quarter-over-quarter from 32.65 in Q4 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Times Interest Earned (2024 - 2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Times Interest Earned for 3 consecutive years, with 1.95 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Times Interest Earned rose 98.31% year-over-year to 1.95; the trailing twelve-month figure through Jun 2026 stood at 5.14 (up 81.49% YoY), and the FY2025 full-year result was 42.09, down 288.6% from the prior year.
- Times Interest Earned advanced to 1.95 in Q2 2026 per APUS's latest filing, from 32.65 in the prior quarter.
- Across five years, Times Interest Earned topped out at 1.95 in Q2 2026 and bottomed at 292.69 in Q3 2025.
- Historically, Times Interest Earned has averaged 55.41 across 3 years, with a median of 10.1 in 2024.
- The sharpest annual moves came in 2025 and 2026: Times Interest Earned tumbled 3084.28% in 2025, then jumped 98.31% in 2026.
- Over 3 years, Times Interest Earned stood at 7.65 in 2024, then tumbled by 327.06% to 32.65 in 2025, then surged by 94.03% to 1.95 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered 1.95, 32.65, and 292.69 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.08 |
| 10 | Apimeds Pharmaceuticals US | 3.65 Mn | 3.65 Mn | - | -1.95 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.95 |
| Dec 31, 2025 | -32.65 |
| Sep 30, 2025 | -292.69 |
| Jun 30, 2025 | -115.55 |
| Mar 31, 2025 | -9.58 |
| Dec 31, 2024 | -7.65 |
| Sep 30, 2024 | -9.19 |
| Jun 30, 2024 | -19.34 |
| Mar 31, 2024 | -10.10 |